OptimizeRx Corp
OPRX Nasdaq· Services-Business Services, Nec
Last close · Oct 27, 2026
$9.06
KIRA · Stoqly’s AI analyst, in plain words
- OptimizeRx Corp had $109M of revenue in fiscal 2025, up 18.8% on the year before. Over five years, revenue changed +20.4% a year on average.
- Its operating margin was 10.7%, up 25.6 pts: of every 100 in sales, about 11 is left after running the business.
- OptimizeRx Corp made $5.1M of net profit in fiscal 2025.
- Free cash flow was $18.7M in fiscal 2025, 17.0% of revenue.
- OptimizeRx Corp owes $2.9M more than it holds in cash, about 0.2 years of operating profit.
Market cap
$170M
P/E
37.8x
Revenue
$109M
Net income
$5.1M
Free cash flow
$18.7M
Operating margin
10.7%
OptimizeRx Corp in 30 seconds · fiscal 2025
Are sales growing?
+18.8%
Yes. Sales grew 18.8% last year.
Does it make a profit?
4.7%
A little. It keeps 4.7% of every sale as profit.
Does profit turn into cash?
17.0%
Yes. 17.0% of sales ends up as free cash.
Is debt under control?
0.2x
Yes. It could repay its debt with 0.2 years of operating profit.
How healthy are the accounts?
8 / 9
Solid. It passes 8 of 9 health tests.
How is the share priced?
37.8x
One share costs 37.8 times its yearly profit per share.
What OptimizeRx Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- OptimizeRx Corp
- CIK
- 0001448431
OptimizeRx Corp · OPRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $61.3M | $62.5M | $71.5M | $92.1M | $109M |
| Revenue growth | 41.5% | 1.9% | 14.5% | 28.8% | 18.8% |
| Gross margin | 58.1% | 62.4% | 60.0% | 64.5% | 67.3% |
| Operating margin | 0.6% | −19.7% | −36.9% | −14.9% | 10.7% |
| Net income | $0.4M | −$11.4M | −$17.6M | −$20.1M | $5.1M |
| Net margin | 0.6% | −18.3% | −24.6% | −21.8% | 4.7% |
| Diluted EPS | $0.02 | −$0.64 | −$1.03 | −$1.10 | $0.27 |
| Cash | |||||
| Cash from operations | $0.7M | $10.7M | −$7.2M | $4.9M | $18.7M |
| Capital expenditure | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M |
| Free cash flow | $0.6M | $10.6M | −$7.3M | $4.8M | $18.7M |
| FCF margin | 1.0% | 16.9% | −10.2% | 5.2% | 17.0% |
| Share buybacks | — | $20.0M | $7.5M | — | — |
| Share count change | 19.3% | 0.5% | −3.7% | 6.8% | 3.9% |
| Debt and strength | |||||
| Cash and short-term investments | $84.7M | $74.1M | $13.9M | $13.4M | $23.4M |
| Debt incl. finance leases | — | — | $38.3M | $34.3M | $26.3M |
| Shareholders' equity | $131M | $126M | $127M | $117M | $128M |
| Net debt / EBITDA | — | — | — | — | 0.2x |
| Current ratio | 12.3x | 11.7x | 3.0x | 2.9x | 3.0x |
| Interest coverage | — | — | −18.2x | −2.2x | 2.2x |
| Returns and quality | |||||
| Return on capital | — | — | −13.8% | −7.9% | 6.6% |
| Return on equity | 0.4% | −8.9% | −13.9% | −16.5% | 4.2% |
| Return on tangible equity | 0.4% | −12.7% | −41.8% | −3,280.6% | 30.9% |
| Piotroski F-score | 6 | 4 | 2 | 5 | 8 |
| Altman Z'' | 18.5 | 18.2 | 1.5 | 1.5 | 3.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
OptimizeRx Corp · OPRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.06 a share, the company is worth $170M: 37.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001448431). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.